Table of contents

Clinical/translational cancer immunotherapy

• Original research: Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes (29 June, 2020)

  Alejandro Meraz-Muñoz, Eitan Amir, Pamela Ng, Carmen Avila-Casado, Claire Ragobar, Christopher Chan, Joseph Kim, Ron Wald, Abhijat Kitchlu
• Original research: Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial (25 June, 2020)

  Federica Cappuccini, Richard Bryant, Emily Pollock, Lucy Carter, Clare Verrill, Julianne Hollidge, Ian Poulton, Megan Baker, Celia Mitton, Andrea Baines, Armin Meier, Guenter Schmidt, Richard Harrop, Andrew Protheroe, Ruth MacPherson, Steven Kennish, Susan Morgan, Selena Vigano, Pedro J Romero, Thomas Evans, James Catto, Freddie Hamdy, Adrian V S Hill, Irina Redchenko
• Original research: Lung metastases share common immune features regardless of primary tumor origin (25 June, 2020)

  Sandra García-Mulero, M Henar Alonso, Julián Pardo, Cristina Santos, Xavier Sanjuan, Ramón Salazar, Victor Moreno, Josep María Piulats, Rebeca Sanz-Pamplona
• Original research: Immune checkpoint inhibitor-associated celiac disease (24 June, 2020)

  Yousef R Badran, Angela Shih, Donna Leet, Meghan J Mooradian, Alexandra Coromilas, Jonathan Chen, Marina Kem, Hui Zheng, Jennifer Borowsky, Joseph Misdraji, Mari Mino-Kenudson, Michael Dougan
• Original research: Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression (24 June, 2020)

  Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, Paul Takam Kamga, Adrien Costantini, Catherine Julie, Alexandre Corjon, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Simon Garinet, Thierry Chinet, Jean-François Emile
• Original research: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study (24 June, 2020)

  Yana G Najjar, Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy Tsai, Kelly Abbate, Barbara Durden, Zeynep Eroglu, Shailender Bhatia, Song Park, Akansha Chowdhary, Sunandana Chandra, Jonathan Kennedy, Igor Puzanov, Marc Ernstoff, Pankit Vachhani, Joseph Drabick, Arun Singh, Tan Xu, Jessica Yang, Richard Carvajal, Daniel Manson, John M Kirkwood, Justine Cohen, Ryan Sullivan, Douglas Johnson, Pauline Funchain, Alexander Shoushtari
• Original research: Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity (24 June, 2020)

  Dawei Chen, Hampartsoum B Barsoumian, Grant Fischer, Liangpeng Yang, Vivek Verma, Ahmed I Younes, Yun Hu, Fatemeh Masropour, Katherine Klein, Christopher Vellano, Joseph Marszalek, Michael Davies, Maria Angelica Cortez, James Welsh
• Original research: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells (24 June, 2020)

  Anne W J Martens, Susanne R Janssen, Ingrid A M Derks, Homer C Adams III, Liat Izhak, Roel van Kampen, Sanne H Tonino, Eric Eldering, Gerritje J W van der Windt, Arnon P Kater
• Original research: Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition (23 June, 2020)

  Andressa S Laino, David Woods, Melinda Vassallo, Xiaozhong Qian, Hao Tang, Megan Wind-Rotolo, Jeffrey Weber
• Original research: DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy (21 June, 2020)

  Yasser Ged, Joshua L Chaim, Renzo G DiNatale, Andrea Knezevic, Ritesh R Kotecha, Maria I Carlo, Chung-Han Lee, Ashley Foster, Darren R Feldman, Min Yuen Teo, Gopakumar Iyer, Timothy Chan, Sujata Patil, Robert J Motzer, A Ari Hakimi, Martin H Voss
• Original research: Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses (18 June, 2020)

  Victoria A Brentville, Rachael L Metheringham, Ian Daniels, Suha Atabani, Peter Symonds, Katherine W Cook, Mireille Vankemmelbeke, Ruhul Choudhury, Poonam Vaghela, Mohamed Gijon, Ghislaine Meiners, Willem-Jan Krebber, Cornelis J M Melief, Lindy G Durrant
• Original research: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study (18 June, 2020)

  Lin Shen, Jun Guo, Qingyuan Zhang, Hongming Pan, Ying Yuan, Yuxian Bai, Tianshu Liu, Qing Zhou, Jun Zhao, Yongqian Shu, Xiaoming Huang, Siyang Wang, Jie Wang, Aiping Zhou, Dingwei Ye, Ting Sun, Yujuan Gao, Silu Yang, Zuobai Wang, Jian Li, Yi-Long Wu
• Original research: Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth (17 June, 2020)

  Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng
• Original research: Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine (17 June, 2020)

  Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon II, Jeffrey Schlom, Caroline Jochems
• Original research: Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors (14 June, 2020)

  Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia-Chi Lin, Chia-Jui Yen, Yee Chao, Bhumsuk Keam, Michael Jameson, Ming-Mo Hou, Yoon-Koo Kang, Ben Markman, Chang-Hsien Lu, Kun-Ming Rau, Kyung-Hun Lee, Lisa Horvath, Michael Friedlander, Andrew Hill, Shahneen Sandhu, Paula Barlow, Chi-Yuan Wu, Yun Zhang, Liang Liang, John Wu, Virginia Paton, Michael Millward
• Original research: Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (17 June, 2020)

  Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Brett G M Hughes, Dirk Schadendorf, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Thomas Eigentler, Brian Stein, Anna C Pavlick, Jessica L Geiger, Ralf Gutzmer, Murad Alam, Emmanuel Okoye, Melissa Mathias, Vladimir Jankovic, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Israel Lowy, Matthew G Fury, Alexander Guminski
• Original research:

  First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE₂-receptor E-type 4 (EP4), in patients with advanced cancers

  (17 June, 2020)

  David S Hong, Aparna Parikh, Geoffrey I Shapiro, Andrea Varga, Aung Naing, Funda Meric-Bernstam, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi, Xingfeng Bao, Aurelien Marabelle
• IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment (12 June, 2020)

  Mélanie Desbois, Coralie Béal, Mélinda Charrier, Benjamin Besse, Guillaume Meurice, Nicolas Cagnard, Yannick Jacques, David Béchard, Lydie Cassard, Nathalie Chaput
• Original research: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (4 June, 2020)

  Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, Caroline Robert, Vanna Chiarion-Sileni, Ana Arance, Céleste Lebbé, Inge Marie Svane, Catriona McNeil, Piotr Rutkowski, Carmen Loquai, Laurent Mortier, Omid Hamid, Lars Bastholt, Brigitte Dreno, Dirk Schadendorf, Claus Garbe, Marta Nyakas, Jean-Jacques Grob, Luc Thomas, Gabriella Liszkay, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Ralf Gutzmer, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Maio
• Original research: Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study (2 June, 2020)

  Kaichao Feng, Yang Liu, Yongtian Zhao, Qingming Yang, Liang Dong, Jiejie Liu, Xiang Li, Zhikun Zhao, Qian Mei, Weidong Han
• Original research: Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma (27 May, 2020)

  Brendan Curti, Marka Crittenden, Steven K Seung, Christopher B Fountain, Roxanne Payne, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick, Walter J Urba
• Original research: Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer (26 May, 2020)

  Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Esther Oomen-De Hoop, Cor H. Van der Leest, Samira El Bouazzaoui, Sander Bins, Stijn L. W. Koolen, Stefan Sleijfer, Astrid A. M. Van der Veldt, Reno Debets, Ron H. N. Van Schaik, Joachim G. J. V. Aerts, Ron H. J. Mathijssen
• Original research: Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer (26 May, 2020)

  Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Shunsuke Kondo, Li-Tzong Chen, Motonobu Osada, Christoph Helwig, Isabelle Dussault, Masafumi Ikeda
• Original research: ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma (26 May, 2020)

  Hailong Sheng, Yan Huang, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Jian Wang, Hui Wang, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao
• Original research: Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer (26 May, 2020)

  Fan Sun, Zong Sheng Guo, Alyssa D Gregory, Steven D Shapiro, Gutian Xiao, Zhaoxia Qu
• Original research: Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial (24 May, 2020)

  Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song
• Original research: Immunomodulatory effects of renin–angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases (24 May, 2020)

  Dora Lucia Vallejo Ardila, Katrina A Walsh, Theodora Fifis, Rita Paolini, Georgios Kastrappis, Christopher Christophi, Marcos Vinicius Perini
• Original research: Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients (24 May, 2020)

  Georg Alexander Rockinger, Philippe Guillaume, Amélie Cachot, Margaux Saillard, Daniel E Speiser, Georges Coukos, Alexandre Harari, Pedro J Romero, Julien Schmidt, Camilla Jandus
• Original research: PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations (20 May, 2020)

  Kellsye P Fabian, Michelle R Padget, Renee N. Donahue, Kristen Solocinski, Yvette Robbins, Clint T. Allen, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
• Original research: Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial (15 May, 2020)

  Sandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, Omid Hamid, Janice M Mehnert, Patrick Terheyden, Kent C Shih, Isaac Brownell, Celeste Lebbé, Karl D Lewis, Gerald P Linette, Michele Milella, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul T Nghiem
• Original research: Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis (15 May, 2020)

  Meghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, Melissa Lumish, Tianqi Chen, Anita Giobbie-Hurder, Douglas B. Johnson, Ryan J. Sullivan, Michael Dougan
• Original research: MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma (7 May, 2020)

  Victor H Engelhard, Rebecca C Obeng, Kara L Cummings, Gina R Petroni, Angela L Ambakhutwala, Kimberly A Chianese-Bullock, Kelly T Smith, Amanda Lulu, Nikole Varhegyi, Mark E Smolkin, Paisley Myers, Keira E Mahoney, Jeffrey Shabanowitz, Nico Buettner, Emily H Hall, Kathleen Haden, Mark Cobbold, Donald F Hunt, Geoffrey Weiss, Elizabeth Gaughan, Craig L Slingluff, Jr
• Original research: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial (5 May, 2020)

  Lu Xie, Jie Xu, Xin Sun, Wei Guo, Jin Gu, Kuisheng Liu, Bingxin Zheng, Tingting Ren, Yi Huang, Xiaodong Tang, Taiqiang Yan, Rongli Yang, Kunkun Sun, Danhua Shen, Yuan Li
• Original research: Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies (5 May, 2020)

  Jason Cham, Li Zhang, Serena Kwek, Alan Paciorek, Tao He, Grant Fong, David Y Oh, Lawrence Fong
• Original research: Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG (5 May, 2020)

  Sarah Knispel, Andreas Stang, Lisa Zimmer, Hildegard Lax, Ralf Gutzmer, Lucie Heinzerling, Carsten Weishaupt, Claudia Pföhler, Anja Gesierich, Rudolf Herbst, Katharina C Kaehler, Benjamin Weide, Carola Berking, Carmen Loquai, Jochen Utikal, Patrick Terheyden, Martin Kaatz, Max Schlaak, Alexander Kreuter, Jens Ulrich, Peter Mohr, Edgar Dippel, Elisabeth Livingstone, Jürgen C Becker, Michael Weichenthal, Eleftheria Chorti, Janine Gronewold, Dirk Schadendorf, Selma Ugurel
• Original research: CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma (5 May, 2020)

  Quan Zhou, Yangyang Qi, Zewei Wang, Han Zeng, Hongyu Zhang, Zhaopei Liu, Qiuren Huang, Ying Xiong, Jiajun Wang, Yuan Chang, Qi Bai, Yu Xia, Yiwei Wang, Li Liu, Le Xu, Bo Dai, Jianming Guo, Yu Zhu, Weijuan Zhang, Jiejie Xu
• Original research: Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment (28 April, 2020)

  Karlyn E Pollack, Max O Meneveau, Marit M Melssen, Kevin T Lynch, Alexander F Koeppel, Samuel J Young, Stephen Turner, Pankaj Kumar, Katia Sol-Church, Ileana S Mauldin, Craig L Slingluff Jr
• Original research: Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma (20 April, 2020)

  Jonathan S Cebon, Martin Gore, John F Thompson, Ian D Davis, Grant A McArthur, Euan Walpole, Mark Smithers, Vincenzo Cerundolo, P Rod Dunbar, Duncan MacGregor, Cyril Fisher, Michael Millward, Paul Nathan, Michael P N Findlay, Peter Hersey, T R Jeffry Evans, Christian Hermann Ottensmeier, Jeremy Marsden, Angus G Dalgleish, Pippa G Corrie, Marples Maria, Margaret Brimble, Geoff Williams, Sintia Winkler, Heather M Jackson, Liliana Endo-Munoz, Candani S A Tutuka, Ralph Venhaus, Lloyd J Old, Dennis Haack, Eugene Maraskovsky, Andreas Behren, Weisan Chen
• Original research: Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors (16 April, 2020)

  Coya Tapia, Phyu P. Aung, Sinchita Roy-Chowdhuri, Mingxuan Xu, Fengying Ouyang, Anas Alshawa, Joud Hajjar, Gopal Singh, Vincent Yang, Lilibeth Castillo, Hung Le, Ravi Murthy, Bettzy Stephen, Kenneth R Hess, Ignacio Wistuba, Aung Naing
• Original research: Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist (16 April, 2020)

  Karin M Knudson, Kristin C Hicks, Yohei Ozawa, Jeffrey Schlom, Sofia R Gameiro
• Original research: Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma (16 April, 2020)

  Won Jin Ho, Ludmila Danilova, Su Jin Lim, Rohan Verma, Stephanie Xavier, James M Leatherman, Marcelo B Sztein, Elana J Fertig, Hao Wang, Elizabeth Jaffee, Mark Yarchoan
• Original research: C reactive protein impairs adaptive immunity in immune cells of patients with melanoma (16 April, 2020)

  Tatsuya Yoshida, Junya Ichikawa, Iulia Giuroiu, Andressa S Laino, Yuhan Hao, Michelle Krogsgaard, Melinda Vassallo, David M Woods, F Stephen Hodi, Jeffrey Weber
• Original research: First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach (8 April, 2020)

  Teilo H Schaller, David J Snyder, Ivan Spasojevic, Patrick C Gedeon, Luis Sanchez-Perez, John H Sampson
• Original research: Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer (7 April, 2020)

  Houssein Abdul Sater, Jennifer L Marté, Renee N Donahue, Beatriz Walter-Rodriguez, Christopher R Heery, Seth M Steinberg, Lisa M Cordes, Guinevere Chun, Fatima Karzai, Marijo Bilusic, Stephanie A Harmon, Ismail Baris Turkbey, Peter L Choyke, Jeffrey Schlom, William L Dahut, Ravi A Madan, Peter A Pinto, James L Gulley
• Original research: Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (26 March, 2020)

  Teresa Amaral, Felix Kiecker, Sarah Schaefer, Henner Stege, Katharina Kaehler, Patrick Terheyden, Anja Gesierich, Ralf Gutzmer, Sebastian Haferkamp, Jochen Uttikal, Carola Berking, David Rafei-Shamsabadi, Lydia Reinhardt, Friedegund Meier, Ante Karoglan, Christian Posch, Thilo Gambichler, Claudia Pfoehler, Kai Thoms, Julia Tietze, Dirk Debus, Rudolf Herbst, Steffen Emmert, Carmen Loquai, Jessica C Hassel, Frank Meiss, Thomas Tueting, Vanessa Heinrich, Thomas Eigentler, Claus Garbe, Lisa Zimmer
• Original research: Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort (26 March, 2020)

  Nicholas Bevins, Shulei Sun, Zied Gaieb, John A Thorson, Sarah S Murray
• Original research: Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate (26 March, 2020)

  Stijn JH Waaijer, Danique Giesen, Takahiro Ishiguro, Yuji Sano, Naofumi Sugaya, Carolina P Schröder, Elisabeth GE de Vries, Marjolijn N Lub-de Hooge
• Original research:

  A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery

  (26 March, 2020)

  Jahangir Ahmed, Louisa S Chard, Ming Yuan, Jiwei Wang, Anwen Howells, Yuenan Li, Haoze Li, Zhongxian Zhang, Shuangshuang Lu, Dongling Gao, Pengju Wang, Yongchao Chu, Chadwan Al Yaghchi, Joel Schwartz, Ghassan Alusi, Nicholas Lemoine, Yaohe Wang
• Original research: Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study (26 March, 2020)

  Nieves Martinez Chanza, Wanling Xie, Majd Issa, Hannah Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Lam, Yousef Zakharia, Rana Mckay, Sumit Shah, Amir Mortazavi, Michael R. Harrison, Spyridon Sideris, Marina D Kaymakcalan, Sarah Abou Alaiwi, Amin H Nassar, Pier Vitale Nuzzo, Anis Hamid, Toni K Choueiri, Lauren C Harshman
• Original research: Phase 2 study of pembrolizumab in patients with advanced rare cancers (17 March, 2020)

  Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, Daniel D Karp, Joud Hajjar, Jordi Rodon Ahnert, Sarina A Piha-Paul, Rivka R Colen, Camilo Jimenez, Kanwal P Raghav, Renata Ferrarotto, Shi-Ming Tu, Matthew Campbell, Linghua Wang, Sarjeel H Sabir, Coya Tapia, Chantale Bernatchez, Michael Frumovitz, Nizar Tannir, Vinod Ravi, Saria Khan, Jeane M Painter, Abulrahman Abonofal, Jing Gong, Anas Alshawa, Lacey M McQuinn, Mingxuan Xu, Sara Ahmed, Vivek Subbiah, David S Hong, Shubham Pant, Timothy A Yap, Apostolia M Tsimberidou, Ecaterina E Ileana Dumbrava, Filip Janku, Siqing Fu, Richard M Simon, Kenneth R Hess, Gauri R Varadhachary, Mouhammed Amir Habra
• Original research: Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity (17 March, 2020)

  Lucas A Horn, Jeffrey Riskin, Heidi A Hempel, Kristen Fousek, Hanne Lind, Duane H Hamilton, Kristen K McCampbell, Dean Y Maeda, John A Zebala, Zhen Su, Jeffrey Schlom, Claudia Palena
• Original research: A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors (15 March, 2020)

  Aung Naing, Justin F Gainor, Hans Gelderblom, Patrick M Forde, Marcus O Butler, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Matthew Taylor, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Jennifer Mataraza, Scott Cameron, Todd M Bauer
• Original research: Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib (15 March, 2020)

  Yang Yang, Mayu Sun, Wenbo Yao, Feng Wang, Xiaoguang Li, Wei Wang, Jingquan Li, Zhihu Gao, Lin Qiu, Rongli You, Chenghua Yang, Qian Ba, Hui Wang
• Original research: Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model (12 March, 2020)

  Jiaji Mao, Minghui Cao, Fang Zhang, Jingzhong Zhang, Xiaohui Duan, Liejing Lu, Zehong Yang, Xiang Zhang, Wangshu Zhu, Qinyuan Zhang, Zhe Wang, Jun Shen
• Original research: Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors (8 March, 2020)

  Maha Mamoor, Michael A Postow, Jessica A Lavery, Shrujal S Baxi, Niloufer Khan, Jun J Mao, Lauren J Rogak, Robert Sidlow, Bridgette Thom, Jedd A Wolchok, Deborah Korenstein
• Original research: Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients (8 March, 2020)

  Orit Itzhaki, Elad Jacoby, Abraham Nissani, Michal Levi, Arnon Nagler, Adva Kubi, Karin Brezinger, Hadar Brayer, Li-at Zeltzer, Meir Rozenbaum, Helly Vernitsky, Gal Markel, Amos Toren, Abraham Avigdor, Jacob Schachter, Michal J Besser
• Original research: Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer (28 February, 2020)

  Michael Overman, Milind Javle, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Al B Benson, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra
• Original research: TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma (28 February, 2020)

  Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Isabelle Bar, Jurgen Corthals, Sofie Wilgenhof, Bart Neyns, Kris Thielemans
• Original research: Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis (27 February, 2020)

  Ssu-Hsueh Tseng, Sung-Taek Park, Brandon Lam, Ya-Chea Tsai, Max A Cheng, Emily Farmer, Deyin Xing, Chien-Fu Hung
• Original research: Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis (26 February, 2020)

  Flora Mulkey, Marc R Theoret, Patricia Keegan, Richard Pazdur, Rajeshwari Sridhara
• Original research: Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) (16 February, 2020)

  Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki, Kentaro Tanaka, Shunsuke Teraoka, Kazuhiro Usui, Kazumi Nishino, Osamu Hataji, Keiichi Ota, Noriyuki Ebi, Sho Saeki, Yuki Akazawa, Motoyasu Okuno, Nobuyuki Yamamoto, Kazuhiko Nakagawa
• Original research: Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma (16 February, 2020)

  Sarah Abou Alaiwi, Wanling Xie, Amin H Nassar, Shaan Dudani, Dylan Martini, Ziad Bakouny, John A Steinharter, Pier Vitale Nuzzo, Ronan Flippot, Nieves Martinez-Chanza, Xiao Wei, Bradley A McGregor, Marina D Kaymakcalan, Daniel Y C Heng, Mehmet A Bilen, Toni K Choueiri, Lauren C Harshman
• Original research: Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer (13 February, 2020)

  Ami N Shah, Lisa Flaum, Irene Helenowski, Cesar A Santa-Maria, Sarika Jain, Alfred Rademaker, Valerie Nelson, Dean Tsarwhas, Massimo Cristofanilli, William Gradishar
• Original research: Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer (12 February, 2020)

  Mingjie Zhang, Lifeng Huang, Guoping Ding, Huilian Huang, Guoliang Cao, Xu Sun, Neng Lou, Qiang Wei, Tao Shen, Xiaodong Xu, Liping Cao, Qiang Yan
• Original research: Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models (10 February, 2020)

  Taiki Kurino, Reiko Matsuda, Ayu Terui, Hiroyuki Suzuki, Tomomi Kokubo, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka, Hiroto Hatakeyama
• Original research: Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors (26 January, 2020)

  Charles Dolladille, Stephane Ederhy, Stéphane Allouche, Querntin Dupas, Radj Gervais, Jeannick Madelaine, Marion Sassier, Anne-Flore Plane, Francois Comoz, Ariel Aron Cohen, Franck Roland Thuny, Jennifer Cautela, Joachim Alexandre
• Original research:

  Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer

  (19 January, 2020)

  Xiao-Xiao Peng, Ruoying Yu, Xue Wu, Shu-Yu Wu, Can Pi, Zhi-Hong Chen, Xu-Chao Zhang, Cun-Yi Gao, Yang W Shao, Li Liu, Yi-Long Wu, Qing Zhou
• Original research: Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models (19 January, 2020)

  Ling Zhang, John S Davies, Carylinda Serna, Zhiya Yu, Nicholas P Restifo, Steven A Rosenberg, Richard A Morgan, Christian S Hinrichs
• Original research: Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy (15 January, 2020)

  Shibin Qu, Tejaswi Worlikar, Amy E Felsted, Anutosh Ganguly, Megan V Beems, Ryan Hubbard, Ashley L Pepple, Alicia A Kevelin, Hannah Garavaglia, Joe Dib, Mariam Toma, Hai Huang, Allan Tsung, Zhen Xu, Clifford Suhyun Cho
• Original research: Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity (13 January, 2020)

  João Manuel Santos, Camilla Heiniö, Victor Cervera-Carrascon, Dafne C A Quixabeira, Mikko Siurala, Riikka Havunen, Ralf Butzow, Sadia Zafar, Tanja de Gruijl, Heini Lassus, Anna Kanerva, Akseli Hemminki
• Original research: Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis (2 January, 2020)

  Johannes Laengle, Julijan Kabiljo, Leah Hunter, Jakob Homola, Sophie Prodinger, Gerda Egger, Michael Bergmann